According to a report by CNBC, a recent study from Harvard University’s Kennedy School indicates that China is rapidly rising in the biotechnology sector and could potentially surpass the United States. The study published the "Critical and Emerging Technologies Index," highlighting that while the U.S. maintains a lead in various fields, the technological gap between the U.S. and China in biotechnology is narrowing, and future developments may significantly alter the global competitive landscape.

The U.S. National Security Commission on Emerging Biotechnology issued a stern warning in an April report stating that if China reaches a pivotal milestone in biotechnology first, the U.S. may never catch up. The commission recommends that the U.S. government invest at least $15 billion in the domestic biotech industry over the next five years, adopting a dual-track strategy to accelerate American innovation and slow down China's progress.

The report points out that China's biotech sector has advanced to the point where European and American pharmaceutical giants have spent billions acquiring its developed cancer drugs. The advantages in China's biotechnology arise from its dominance in pharmaceutical manufacturing and a richer talent pool compared to the U.S. The flexibility of China's regulatory environment allows for quicker product launches, contrasting with the prolonged approval processes in the U.S.

While China's biotechnology industry is actively advancing, the U.S. biotech hubs of Cambridge and Boston are facing layoffs and lab vacancies. The report raises concerns that China's growing dominance in biotechnology could become another means for Beijing to exert pressure on the U.S. and other countries, much like the restrictions on rare earth materials have impacted the automotive industry.